ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis.
Han Bao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.